In particular, 6 of 21 (28.6%) triple-negative BC patients, 3 of 21 (14.3%) Luminal B/HER2+ BC patients, 2 of 19 (10.5%) Luminal B/HER2- BC patients, 1 of 14 (7.1%) Luminal A BC patients and 1 of 7 (14.3%) patients with unknown molecular subtype were carriers of PVs (Figure 6A). The gene discussed is ERBB2; the disease is breast cancer.